StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Pixantrone

HCID 134019
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
144510-96-3
Standard-SMILES
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O
InChIKey
PEZPMAYDXJQYRV-UHFFFAOYSA-N
Summenformel
C17H19N5O2
Durchschnittliche Molmasse
325,4 g/mol
Monoisotopische Masse
325,15387485

Überblick

Pixantrone is a member of isoquinolines.

Namen und Bezeichner

Bevorzugter Name
Pixantrone
IUPAC
6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
Englischer Name
Pixantrone
Summenformel
C17H19N5O2
Molmasse
325.37

Namen und Synonyme

Pixantrone144510-96-36,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione6,9-Aea-biqdoPixantronaF5SXN2KNMRBBR-27786,9-bis((2-aminoethyl)amino)benzo[g]isoquinoline-5,10-dioneBBR27786,9-Bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dioneBenz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-
Weitere Namen anzeigen
CS-1359Pixantrone, BBR 2778BBR 2778Pixantrone diformate salt6,9-Bis[(2-aminoethyl)amino]benz[g]isoquinoline-5,10-dione
DTXSID101627445,8-Bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dioneBenz(g)isoquinoline-5,10-dione, 6,9-bis((2-aminoethyl)amino)-pixantronum6,9-bis(2-aminoethylamino)benzo(g)isoquinoline-5,10-dioneRefChem:929364DTXCID1085235SID225144373

Datenbank-Bezeichner

CAS
144510-96-3、144675-97-8
PubChem CID
134019

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1
Polarare Oberfläche (TPSA)
123 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
7
Frei drehbare Bindungen
6
Schwere Atome
24
Formalladung
0
Komplexität
472

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15

Physikochemische Eigenschaften

Schmelzpunkt
173 °C · >173°C (dec.)
Siedepunkt
650 · 650.0±55.0 °C(Predicted)
Dichte
1.405 · 1.405
storage temp.
Refrigerator
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
pka
9.34 · 9.34±0.10(Predicted)
Aggregatzustand
Solid
Farbe
Dark Blue to Very Dark Blue

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H300 (50%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P308+P316, P316, P318, P320, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 2 (50%)

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingAnthracyclines, which may be effective second line treatments for NHL have limited use in therapy because of cumulative cardiotoxicity which may result in irreversible damage to cardiac tissue. [2]
Pharmacodynamics · 1 Eintrag

Pixantrone has a wide range of antitumor activity, especially in terms of treating leukemias and lymphomas [3]. Pixantrone lacks cardio-toxic effects. It has postulated that his is because of its redox inactivity and lack and inhibition of doxorubicinol formation in human myocardium. [3]

Mechanism of Action · 1 Eintrag

Pixantrone is an aza-anthracenedione which acts as a DNA intercalator. By intercalating between DNA, with modest affinity, it stimulates DNA cleavage by topoisomerase II. (Pixantrone acts as a poison to topoisomerase II by stabilizing protein-DNA complexes which are usually transient, giving rise to double stranded DNA breaks.) However, pixantrone is believed to have additional mechanisms of action as its potency does not correlate to the degree of double stranded DNA breaks observed. It has been postulated that this second mechanism may be pixantrone-DNA adduct formation. [1] It is important to note that the formation of a pixtantrone-DNA adduct requires pixantrone activation by formaldehyde. Formadehyde may be generated in vitro by hydrogen peroxide, and is derived by various sources in biological systems. It is present in low levels as a result of normal metabolism, and may be present in elevated levels in some haematolgical malignancies. [1] The formation of pixantrone-DNA adducts is thus feasible, and it is believed that a long pixantrone-DNA adduct half life has the potential to maximize DNA damage. It may do so by enhancing the disruption of DNA replication and transcription, and potentially by encourage apoptosis. [1] In explanation of pixantrones lack of cardiotoxicity, it has been elucidated that pixantrone is structurally similar to mitoxantrone; however, instead of a 5,8-dihydroxyphenyl ring (thought to be responsible for cardiotoxicity) it has a nitrogen heteroatom. This nitrogen heteroatom helps to create additional hydrogen bonding sites amd increases pixantrone interaction with DNA and topoisomerase II. [2] Pixantrone's lack of a hydroquinone is believed to render it resistant to one electron reduction. In contrast, doxorubicin - which contains a hydroquinone - experiences one electron redox cycling and ROS formation via NADH dehydrogenase. [3] Pixantrone also does not bind iron, and thus does not produce ROS by redox cycling between oxidative states of iron, as other anthracyclines do. [2] The first line agent doxorubicin is cardiotoxic, in part, due to its ability to redox activate the superoxide anion and hydrogen peroxide, and form a long-lived secondary alcohol metabolite: doxorubicinol. [3] Clearance of doxorubicin from myocardial tissue is incomplete, and it can be found months or years after the last administration. [3] In doxorubicin treated ex vivo cardiac strips, pixantrone formed an N-dealkylated product that inhibited metabolism of residual doxorubicin into doxorubicinol. Additionally, in ex vivo human myocardial strips (doxorubicin naive, and doxorubicin pretreated) pixantrone showed high cardiac uptake without formation of superoxide anion or hydrogen peroxide. Pixantrones lack of cardiotoxicity is thus attributed to its redox inactivity and inhibition of doxorubicinol formation. [3]

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 52402
HRID 52402als Produkt
Reaktionsgleichung von HRID 269708
HRID 269708als Edukt
Reaktionsgleichung von HRID 862158
HRID 862158als Produkt
Reaktionsgleichung von HRID 862162
HRID 862162als Produkt
Reaktionsgleichung von HRID 862163
HRID 862163als Produkt
Reaktionsgleichung von HRID 862164
HRID 862164als Edukt
Reaktionsgleichung von HRID 1720233
HRID 1720233als Produkt
Reaktionsgleichung von HRID 1720236
HRID 1720236als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID
DTXSID10162744
ChEMBL
CHEMBL167731
ChEBI
CHEBI:135945
UNII
F5SXN2KNMR
EC Number
680-661-5
Nikkaji
J580.321G
Biological Half-LifeHalf life ranges from 14.7 to 31.9 hours.
Metabolism/Metabolites · 1 Eintrag

Pixantrone does not form secondary alcohol metabolites. [2] Pixantrone hydrolyzes extensively to CT-45886 which is believed to inhibit doxol formation by displacing DOX from the active site of reductases. CT4889 and CT-45890 are also formed.[3]

MeSH Pharmacological Classification · 1 Eintrag

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.

Absorption, Distribution and Excretion · 4 Einträge

Intravenous administration results in a rapid distribution followed by a slow elimination. [2] In ex vivo myocardial strips, pixantrone is taken up to a higher degree than mitoxantrone. In myocardial strips which are doxorubicin naive pixantrone displays higher uptake than in DOX-loaded myocardial strips. DOX clearance causes membrane effects which may be responsible for this observation. DOX clearance involves rapid passive diffusion through one side of the membrane followed by "flip flop" reorientation of the lipid bilayer. This disorganization of lipids is believed to impair membrane penetration by pixantrone. [3]

Fecally and renally excreted. Urinary elimination of unchanged drug is less than 10%. [2]

9.7-29.7 L/kg. [2]

Plasma clearance is 0.75 - 1.31 L/h/kg. [2]

Anwendungen · 2 Einträge

BeschreibungIn May 2012, pixantrone was approved by the European Commission as a single agent for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adult patients who have failed on at least two previous therapies. Pixantrone (also known as BBR- 2778) is an anthracycline analogue that was specifically designed to address the cardiotoxicity seen in earlier agents by replacement of a 1,4- dihydroxyanthracene-9,10-dione core with a benzoisoquinoline-5,10-dione ring system. Pixantrone inhibits topoisomerase II by intercalation with DNA and is also believed to form covalent adducts with the N-2 amino group of guanine via a formaldehyde aminal formed with the primary amino groups. Pixantrone is less cytotoxic than other anthracycline derivatives, but shows good antitumor activity in vivo in a variety of preclinical tumor models, including leukemia and lymphoma models. Pixantrone also demonstrated significantly reduced cardiotoxicity in preclinical models compared with the anthracyclines doxorubicin and mitroxantrone. Pixantrone was synthesized by Friedel–Crafts reaction of pyridine-3,4-dicarboxylic acid anhydride with 1,4-difluorobenzene to give a ketoacid that was cyclized to the tricyclic core by treatment with fuming sulfuric acid at 140℃. Reaction of the resulting 6,9-difluorobenzoisoquinoline-5-10-dione with ethylenediamine followed by careful pH adjustment and treatment with maleic acid gave pixantrone in good overall yield and purity.

VerwendenPixantrone is an antineoplastic drug belonging to group of antitumor antibiotics. Pixantrone is an anlogue of Mitoxantrone (M373425) and is just as potent in the treatment of multiple sclerosis with fewer toxic effects on cardiac tissue. Studies suggest that Pixantrone significantly reduces amyloid beta (A beta(1-42)) neurotoxicity, a mechanism implicated in Alzheimer's disease.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Benz[g]isoquinoline-5,10-dione, 6,9-dihydroxy-isoquinoline-5,10-dione">6,9-difluorobenzoisoquinoline-5,10-dionePyridine-3,4-dicarboxylic anhydride1,2-DiaminoethanPyridin-3,4-dicarbonsure